No news has been heard of ever since its drug pricing negotiations broke down in August last year. However, RET inhibitors are a hard-to-forego treatment option for a small number of lung cancer patients.

There are only 2 RET-targeted therapies – ‘Gavreto (pralsetinib),’ which Roche Korea introduced from Blueprint Medicines, and ‘Retevmo (selpercatinib’ by Lilly Korea – currently approved in Korea. Both drugs have attempted insurance reimbursement in Korea but were denied reimbursement last year.

Adding Roche's market withdrawal for Gavreto, it would be hard for Gavreto to be listed for reimbursement in Korea. The case is not much better for Retevmo either.